AGIO vs IRON: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

IRON is the larger of the two ($3.40B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 2.01). AGIO is the smaller challenger ($1.69B), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, AGIO fits: analysts expect its revenue to rise 88% next year, against 0% for IRON. If you believe IRON's main driver (Bitopertin: APOLLO succeeded, approval is next) pays off sooner, IRON fits.

AGIO vs IRON: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAGIOIRONWhat it tells you
Market cap$1.69B$3.40BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-9.14-12.24Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.622.01Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range25% of range58% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.734.77How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how AGIO and IRON affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AGIO and IRON share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AGIO and IRON exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Agios Pharmaceuticals (AGIO) do?

Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia (US launch January 2026; PYRUKYND was also approved for thalassemia in the EU in late May 2026). The company is pursuing accelerated approval of mitapivat in sickle cell disease. The FDA granted Priority Review to that application in 2026 with a decision expected by November 1, 2026, but in late October it extended the goal date by three months to February 1, 2027, after asking for more information on whether a REMS (a formal risk-management program) is needed and classifying Agios' response as a major amendment. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).

Full AGIO guide

What does Disc Medicine (IRON) do?

Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its programs aim to modify the biological pathways behind red blood cell formation and function, principally heme biosynthesis and iron homeostasis. The lead pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), selcodebart (DISC-0974, an anti-hemojuvelin antibody) for anemia of myelofibrosis, and DISC-3405 (an anti-TMPRSS6 antibody) being studied in conditions like polycythemia vera and sickle cell disease. The current company was formed when Disc Medicine reverse-merged into Gemini Therapeutics in December 2022 and began trading under the ticker IRON.

Full IRON guide

AGIO vs IRON: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • AGIO drivers: Mitapivat franchise expansion; Sickle cell decision, now February 2027.
  • IRON drivers: Bitopertin: APOLLO succeeded, approval is next; Selcodebart (DISC-0974) in anemia of myelofibrosis.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. For IRON, disc Medicine is a clinical-stage company with no product revenue, so it is not profitable and its value rests on programs that can still fail.

AGIO or IRON: which should you pick?

If the story you believe is AGIO's (Mitapivat franchise expansion), AGIO is the more direct way to own it; if it is IRON's (Bitopertin: APOLLO succeeded, approval is next), IRON is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AGIO and IRON guides.

AGIO vs IRON: the full fundamentals

AGIO. Agios trades at about 12 times trailing revenue, down from about 19 times in October as sales grew and the stock fell on the FDA extension, and the valuation still rests on the sickle cell opportunity rather than current earnings. Analysts expect revenue of about $185 million in 2026 and $349 million in 2027, with losses narrowing to about -$3.00 per share in 2027. The nine covering analysts carry a buy rating and a mean target of about $46 (BofA trimmed its target to $48 from $50 after the quarter), well above the price.

IRON. As a clinical-stage biotech, Disc has no product sales, so traditional metrics like P/E do not apply and the company is valued on its pipeline's expected value and its cash. Its September cash plus the October raise comes to roughly $1.2 billion, about a third of its market value near $3.4 billion, so a big share of the price is the balance sheet plus the value the market assigns to a bitopertin approval and to selcodebart and DISC-3405. The mean analyst target among 13 tracked by Yahoo was about $128 in November 2026, with Guggenheim starting coverage at $132, and the FDA resubmission and mid-2027 decision are the next major events.

Headline figures (approximate, November 2026): AGIO shows revenue (ttm) ~$141M, q3 2026 revenue ~$55.4M (vs ~$12.9M a year earlier), ahead of ~$52M expected, q3 2026 eps ~-$1.09 vs ~-$1.23 expected, net loss (ttm) ~-$373M; free cash flow ~-$264M; IRON shows revenue (ttm) ~$0 (pre-revenue, clinical stage); ~$44 million expected for 2027, net loss (ttm) ~$243 million (EPS ~-$6.34), q3 2026 net loss ~$59.5 million; EPS -$1.53 vs -$1.71 estimate, cash and investments (sept. 30, 2026) ~$683 million, plus ~$486 million net raised in October; ~$61 million debt.

The bottom line: AGIO vs IRON

AGIO and IRON are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AGIO and IRON exposure against your real portfolio. It is not an investment adviser.

Wondering how AGIO or IRON fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Agios Pharmaceuticals

Ask Walnut's AI anything about AGIO and see how it fits what you own.

FAQ

What is the difference between AGIO and IRON?

+

Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AGIO or IRON the better stock?

+

Neither is universally better. IRON is the larger incumbent; AGIO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AGIO or IRON?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AGIO and IRON?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AGIO vs IRON?

+

AGIO: Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. The business now depends almost entirely on a single molecule, so a negative trial or regulatory setback is materially damaging; tebapivat's discontinuation in both MDS and sickle cell in 2026 removed the main backup. The sickle cell decision, pushed to February 1, 2027, is binary, could come with a REMS that limits uptake, and accelerated approval would require a confirmatory trial that could still fail. Sickle cell and thalassemia are competitive markets with gene therapies, Novo Nordisk's etavopivat and other novel agents. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is solid today, sustained losses without pipeline success would eventually pressure it. IRON: Disc Medicine is a clinical-stage company with no product revenue, so it is not profitable and its value rests on programs that can still fail. APOLLO's success lowers but does not remove regulatory risk: the February 2026 complete response letter for bitopertin is a reminder that the FDA can ask for more, and a decision is not expected until around mid-2027. Selcodebart and DISC-3405 are still in Phase 2 or earlier, and disappointing data at ASH in December 2026 or at later readouts could weigh on the stock. Dizziness affected half of APOLLO patients, which could matter for labeling and uptake. The shares traded at $74.78 on November 20, 2026, still well below their 52-week high of $99.50. The company burns roughly $60 million a quarter, and the October 2026 offering of about $486 million net shows it will sell stock when needed, which dilutes existing shareholders. Even successful drugs face commercial risk in small rare-disease markets, competition from established therapies, manufacturing and reimbursement hurdles, and the concentration risk of a pipeline built around a few key programs. The stock is highly volatile and pays no dividend.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AGIO or IRON; figures are approximate and dated (as of November 2026). Verify current data before investing.